Display options
Cite
Mönch D, Bode-Erdmann S, Kalla J, et al. A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. Oncotarget. 2018;9(29):20781-20794doi: 10.18632/oncotarget.25111.
Mönch, D., Bode-Erdmann, S., Kalla, J., Sträter, J., Schwänen, C., Falkenstern-Ge, R., Klumpp, S., Friedel, G., Ott, G., & Kalla, C. (2018). A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. Oncotarget, 9(29), 20781-20794. https://doi.org/10.18632/oncotarget.25111
Mönch, Dina, et al. "A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy." Oncotarget vol. 9,29 (2018): 20781-20794. doi: https://doi.org/10.18632/oncotarget.25111
Mönch D, Bode-Erdmann S, Kalla J, Sträter J, Schwänen C, Falkenstern-Ge R, Klumpp S, Friedel G, Ott G, Kalla C. A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy. Oncotarget. 2018 Apr 17;9(29):20781-20794. doi: 10.18632/oncotarget.25111. eCollection 2018 Apr 17. PMID: 29755689; PMCID: PMC5945506.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Apr 17;9(29):20781-20794. doi: 10.18632/oncotarget.25111. eCollection 2018 Apr 17.

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Oncotarget

Dina Mönch, Sabine Bode-Erdmann, Jörg Kalla, Jörn Sträter, Carsten Schwänen, Roger Falkenstern-Ge, Siegfried Klumpp, Godehard Friedel, German Ott, Claudia Kalla

Affiliations

  1. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
  2. Department of Clinical Pathology, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany.
  3. University of Tübingen, 72074 Tübingen, Germany.
  4. Institute of Pathology, Schwarzwald-Baar-Klinikum, 78052 Villingen-Schwenningen, Germany.
  5. Institute of Pathology, 73730 Esslingen, Germany.
  6. Clinic of Internal Medicine, Oncology/Hematology, Gastroenterology and Infectiology, Klinikum Esslingen, 73730 Esslingen, Germany.
  7. Center for Pulmonology and Thoracic Surgery, Klinik Schillerhöhe, 70839 Stuttgart-Gerlingen, Germany.
  8. Hospital Pharmacy, Robert-Bosch-Krankenhaus, 70376 Stuttgart, Germany.

PMID: 29755689 PMCID: PMC5945506 DOI: 10.18632/oncotarget.25111

Abstract

Malignant pleural mesothelioma (MPM) is a neoplasm with inferior prognosis and notorious chemotherapeutic resistance. Targeting aberrantly overexpressed kinases to cure MPM is a promising therapeutic strategy. Here, we examined ALK, MET and mTOR as potential therapeutic targets and determined the combinatorial efficacy of ALK and mTOR targeting on tumor cell growth

Keywords: ALK; combination therapy; crizotinib; pleural mesothelioma; rapamycin

Conflict of interest statement

CONFLICTS OF INTEREST All authors have no conflicts of interest to declare.

References

  1. Oncotarget. 2014 Sep 30;5(18):8737-49 - PubMed
  2. Mol Cell Biol. 2009 Aug;29(15):4235-49 - PubMed
  3. PLoS One. 2014 Sep 15;9(9):e105919 - PubMed
  4. J Biol Chem. 2009 Mar 20;284(12):8023-32 - PubMed
  5. Cell Death Dis. 2015 May 07;6:e1757 - PubMed
  6. Oncotarget. 2015 Oct 6;6(30):30149-64 - PubMed
  7. Epigenomics. 2015 Oct;7(7):1137-53 - PubMed
  8. Sci Rep. 2016 Sep 13;6:32992 - PubMed
  9. Clin Cancer Res. 2011 Aug 1;17(15):5082-92 - PubMed
  10. J Clin Oncol. 2012 Jan 20;30(3):308-15 - PubMed
  11. J Thorac Cardiovasc Surg. 2010 May;139(5):1233-40 - PubMed
  12. J Thorac Oncol. 2014 Mar;9(3):307-15 - PubMed
  13. Eur J Cancer. 2013 Nov;49(16):3462-70 - PubMed
  14. Curr Top Dev Biol. 2015;114:67-91 - PubMed
  15. Int J Cancer. 2003 May 1;104(5):603-10 - PubMed
  16. Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9 - PubMed
  17. Anticancer Res. 2014 May;34(5):2589-92 - PubMed
  18. Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115 - PubMed
  19. Am J Pathol. 2011 Jan;178(1):296-305 - PubMed
  20. Eur Respir J. 2010 Mar;35(3):479-95 - PubMed
  21. J Clin Oncol. 2007 Jun 10;25(17):2406-13 - PubMed
  22. Genes Cancer. 2010 May 1;1(5):493-505 - PubMed
  23. Cancer Res. 2006 Jan 1;66(1):352-61 - PubMed
  24. Cancer Res. 2009 Sep 15;69(18):7338-46 - PubMed
  25. Clin Cancer Res. 2012 Mar 1;18(5):1472-82 - PubMed
  26. J Clin Pathol. 2014 Jan;67(1):33-9 - PubMed
  27. Lung Cancer. 2017 Feb;104:65-69 - PubMed
  28. J Exp Clin Cancer Res. 2015 Oct 06;34:112 - PubMed
  29. J Thorac Oncol. 2011 Nov;6(11):1938-45 - PubMed
  30. Mol Cancer Res. 2014 Oct;12(10):1460-9 - PubMed
  31. N Engl J Med. 2014 Nov 20;371(21):1963-71 - PubMed
  32. Sci Transl Med. 2012 Feb 8;4(120):120ra17 - PubMed
  33. Am J Pathol. 2012 May;180(5):1772-80 - PubMed
  34. Semin Cancer Biol. 2011 Oct;21(4):267-75 - PubMed
  35. Nature. 2008 Oct 16;455(7215):975-8 - PubMed
  36. Biochem Biophys Res Commun. 1999 Sep 16;263(1):94-9 - PubMed
  37. J Thorac Oncol. 2017 Aug;12 (8):e116-e118 - PubMed
  38. J Clin Invest. 2008 Sep;118(9):3065-74 - PubMed
  39. Nature. 2008 Oct 16;455(7215):967-70 - PubMed
  40. Oncotarget. 2015 Nov 24;6(37):40268-82 - PubMed
  41. Oncotarget. 2015 Nov 24;6(37):40255-67 - PubMed
  42. Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 - PubMed
  43. Carcinogenesis. 2009 Jul;30(7):1097-105 - PubMed
  44. J Thorac Oncol. 2011 May;6(5):864-74 - PubMed
  45. Cell. 2017 Mar 9;168(6):960-976 - PubMed
  46. J Thorac Oncol. 2015 Feb;10(2):387-91 - PubMed
  47. Ann Cardiothorac Surg. 2012 Nov;1(4):428-37 - PubMed
  48. Cancer Res. 2006 Feb 1;66(3):1500-8 - PubMed
  49. Oncotarget. 2017 Apr 11;8(34):56518-56532 - PubMed
  50. Clin Cancer Res. 2005 Mar 15;11(6):2300-4 - PubMed
  51. J Thorac Oncol. 2011 May;6(5):852-63 - PubMed
  52. Cancer Res. 2006 Aug 15;66(16):7864-9 - PubMed
  53. Cell Death Differ. 2005 Nov;12 Suppl 2:1509-18 - PubMed
  54. PLoS Biol. 2009 Feb 10;7(2):e38 - PubMed
  55. Cancer. 2009 Jul 15;115(14):3204-16 - PubMed
  56. J Clin Oncol. 2008 Apr 1;26(10):1603-10 - PubMed
  57. Cancer Treat Rev. 2013 Dec;39(8):839-50 - PubMed
  58. Oncogene. 2007 Mar 22;26(13):1932-40 - PubMed

Publication Types